Home » Topics » BioWorld Science, Nephrology

BioWorld Science, Nephrology
RSS

Cytochroma begins first of two identical phase III studies of CTAP-101

Sep. 21, 2012

Nymox provides update on phase III BPH study

Sep. 19, 2012

Takeda obtains U.K. license for erectile dysfunction medication

Sep. 14, 2012

Santaris Pharma discloses new oligonucleotides

Sep. 12, 2012

Targacept to develop TC-5214 in overactive bladder

Sep. 6, 2012

New tamsulosin prodrugs prepared by Synthon

Sep. 6, 2012

AlloCure begins phase II study in acute kidney injury

Sep. 5, 2012

Adenosine-based therapy shows promise for the treatment of priapism

Sep. 4, 2012

Phase I/II data suggest transrectal administration of PRX-302 is well tolerated in BPH

Sep. 3, 2012

New data presented on Xiaflex in Peyronie's disease

Aug. 30, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 14, 2026.
ASGCT 2026: Circular RNA, the new beast in gene and cell therapy
BioWorld
Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
Alzheimer’s, beyond the brain
BioWorld
Researchers at Daping Hospital in China have reported that liver-targeted delivery of the APOE3-Christchurch (APOE3Ch) variant, a rare protective form of...
News in brief
BioWorld Asia
BioWorld Asia briefs for May 12, 2026
Advancing the 'best of both' – BMS, Hengrui enter $15.2B deal
BioWorld
In a deal potentially worth up to $15.2 billion, Jiangsu Hengrui Pharmaceuticals Co. Ltd. is joining efforts with Bristol Myers Squibb Co. to advance 13 early...